Advertisement

Topics

Latest "Study of Anti-reflux Medication as a Potential Treatment for Glue Ear in Children" News Stories - Page: 4

17:03 EDT 26th March 2019 | BioPortfolio

Here are the most relevant search results for "Study of Anti-reflux Medication as a Potential Treatment for Glue Ear in Children" found in our extensive news archives from over 250 global news sources.

More Information about Study of Anti-reflux Medication as a Potential Treatment for Glue Ear in Children on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Study of Anti-reflux Medication as a Potential Treatment for Glue Ear in Children for you to read. Along with our medical data and news we also list Study of Anti-reflux Medication as a Potential Treatment for Glue Ear in Children Clinical Trials, which are updated daily. BioPortfolio also has a large database of Study of Anti-reflux Medication as a Potential Treatment for Glue Ear in Children Companies for you to search.

Showing "Study Anti reflux Medication Potential Treatment Glue Children" News Articles 76–100 of 44,000+

Tuesday 26th March 2019

Are Kids' Ball Pits Jumping With Germs?

TUESDAY, March 26, 2019 -- If the cacophony of children screaming and throwing tiny plastic balls everywhere hasn't prompted you to forgo ball pits, a new study may just send you scurrying for the door. The research found that ball pits in physical...


ENDO: Levothyroxine Does Not Up Fertility in Women With TPO Ab

TUESDAY, March 26, 2019 -- For euthyroid women with thyroid peroxidase antibodies and a history of miscarriage or infertility, levothyroxine does not result in an increased rate of live births versus placebo, according to a study published online...

Using Tumor Radiomics to Tag NSCLC Chemo Response (CME/CE)

(MedPage Today) -- Peritumoral data may accurately reflect tumor microenvironment, assist treatment selection


SHAPE Doctors Urge People to Consider Coronary Calcium Score Before Stopping Aspirin

Individuals with a calcium score above 100 should think twice about stopping aspirin. The higher the calcium score the more likely aspirin benefit exceeds harm. PALO ALTO, Calif. (PRWEB) March 26, 2019 Leading preventive cardiologists and academic cardiovascular specialists from the Society for Heart Attack Prevention and Eradication (SHAPE), (http://www.shapesociety.org), a non-profit organizati...

Lipella Pharmaceuticals Received FDA IND Approval for Phase-2a Oncology Supportive Care Drug Study

LP-10, which has received FDA Orphan Drug designation, has now obtained IND approval for Phase-2a, multi-center, double-blind, controlled, clinical trial for hemorrhagic cystitis. Lipella Pharmaceuticals Inc., a clinical stage biopharmaceutical company based in Pittsburgh, PA, anno

Cidara Therapeutics Announces Multiple Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Six poster presentations include new analyses from Phase 2 STRIVE clinical trial of rezafungin Four oral presentations include first scientific presentation of new data highlighting the potential of its Cloudbreak antiviral conjugates (AVCs) for influenza Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel...

Kohl’s Donates $5 Million to Children’s Hospital of Wisconsin to Enhance Mental Health Services

Building on Kohl’s commitment to family health and wellness, funding will improve access to critical mental health services for Wisconsin children and families In support of the company’s broader Corporate Social Responsibility (CSR) platform focused on family health and wellness, Kohl's (NYSE: KSS) today announced it will donate $5 milli...

Aphios Granted European Patent for Novel Bryostatin to Treat Alzheimer’s Disease, HIV-1, and Cancers

Aphios Corporation today announced that it has been granted European Patent No. 2 925 315 B1 entitled “Bryoid Compositions, Methods of Making and Use Thereof,” for the composition of matter of a novel Bryostatin, method of manufacturing and for use in the treatment of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, Down’s syndrome, H...

Tarveda Therapeutics to Present Nonclinical Data on PEN-221 in Combination with Epigenetic Modulation at the 2019 AACR Annual Meeting

- Data demonstrate how an HDAC inhibitor increases the tumor expression of SSTR2 with synergy of efficacy - Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing a new class of potent and selective miniature drug conjugates (Pentarins®) for the treatment of patients with a wide range of solid tumors,

Akoya Biosciences’ Multiplex Immunofluorescence Technology for Cancer Research to be Featured at AACR 2019

Company to present data sets from recently launched high-parameter, spatial biology imaging platforms for discovery through clinical and translational research Akoya Biosciences, Inc., today announced that data from its new line of multiplex immunofluorescence imaging platforms for high-parameter, spatially resolved biomarker analysis will be presented...

Charles River Laboratories Highlights Commitment to Oncology Research at 2019 AACR Annual Meeting

Researchers will highlight work in BRCA-deficient and rare pediatric cancers Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of oncology experts will attend the American Association for Cancer Research (AACR) Annual Meeting, with 19 scientific posters and two oral presentations to highlight its enhanced o...

New Claritag Advanced Cryogenics Skincare Solution Introduces At-Home Beauty Options

Innovative device easily removes pesky skin tags; achieve dermatologist-quality results without the cost Claritag™, the leading beauty solution for at-home skin tag removal, has optimized the design of its cryogenics skincare product. Developed by leading dermatologists and skincare professionals, Claritag’s innovative proprietary te

Evaluation of Elecsys HIV combi PT Assay for HIV Diagnosis

This study evaluated the clinical performance of the Elecsys HIV combi PT assay, which was designed with a pretreatment step to enhance early detection and increase sensitivity and specificity. American Journal of Clinical Pathology

Sleep Disorders in Early Psychosis

This study examined the prevalence and characteristics of clinical sleep disorders in patients experiencing early psychosis. Schizophrenia Bulletin

Predictive Models for Patient-reported Spine Surgery Outcomes

This study evaluated predictive models for patient-reported outcomes in elective degenerative spinal surgery with respect to study design, accuracy, reliability, variance, and utility. Neurosurgical Focus

Aldeyra's eye drug meets main goal in late-stage study, shares surge

Aldeyra Therapeutics Inc said on Tuesday its drug reproxalap to treat a form of allergic reaction to the eye met the main goal in a late-stage trial, sending shares up more than 60 percent.

Spinal surgeon loses appeal in case of woman left disabled after heparin injection

A consultant neurosurgeon was negligent in giving a patient antithrombotic treatment only three hours after spinal surgery, the Court of Appeal has ruled.1Three senior judges unanimously dismissed...

Can-Fite's shares hit after failure of mid-stage liver cancer study of namodenoson https://www.firstwordpharma.com/node/1631373  $CANF

Can-Fite's shares hit after failure of mid-stage liver cancer study of namodenoson https://www.firstwordpharma.com/node/1631373  $CANF

BriaCell to Announce Early Efficacy Data of Lead Candidate in Combination with KEYTRUDA® at AACR Annual Meeting

BriaCell Therapeutics Corp. (TSXV:BCT) (OTC:BCTXF) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce it is finalizing the analysis of the initial efficacy data of the first six patients in the combination study of its lead candidate, Bria-IMT™, with pembrolizumab (KEYTRUDA®; manufactur...

Arix Bioscience’s portfolio company Autolus announces positive safety data for AUTO3 ahead of inaugural R&D day

Updated data from the ongoing AMELIA Phase I/II study showed that all six patients treated at the highest dose achieved minimal residual disease negative complete responses

Prophylactic Nipple-Sparing Mastectomy: Longer-Term Data

The most comprehensive study yet of this technique found no cases of breast cancer at 53 months, suggesting it is safe. Medscape Medical News

Novo Nordisk's Ozempic outclasses Januvia with new data in type 2 diabetes

Novo Nordisk has revealed new dose-specific Phase 3a data for its glucagon-like peptide-1 (GLP-1) analogue Ozempic (oral semaglutide), indicating that the drug achieved “superior reductions” in blood sugar, and body weight compared to MSD’s Januvia (sitagliptin 100 mg). The therapy was tested in in type 2 diabetes patients whose condition was inadequately controlled with metformin, with or w...

Emergency Department Subgroup Study Showed Hi-VNI® Technology Had Similar Outcomes to Non-invasive Positive Pressure Ventilation in Management of Respiratory Distress Among Acute Decompensated Heart Failure Patients

Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology, today announced that a paper published in the American Journal of Emergency Medicine, titled “HVNI vs NIPPV in the treatment of Acute Decompensated Heart Failure: subgroup analysis of a multi-center tr...

Aldeyra's experimental drug reproxalap hits main goal in Phase III allergic conjunctivitis study https://www.firstwordpharma.com/node/1631347  $ALDX

Aldeyra's experimental drug reproxalap hits main goal in Phase III allergic conjunctivitis study https://www.firstwordpharma.com/node/1631347  $ALDX

Initial Phase 2 Data From an IMV Clinical Study Continues to Demonstrate DPX-Survivac’s Prior Trend as a Potential Monotherapy Treatment for Advanced Ovarian Cancer

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced preliminary data from the phase 2 cohort of the DECIDE clinical study. Six patients receiving DPX-Survivac monotherapy with intermittent low-dose cyclophosphamide (mCPA) have reached the first CT scan assessment with key related findings as follows: ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks